Terumo Corporation · TSE:4543

Terumo — Investor Presentation (December 2016)

17 slides from Terumo's investor presentation, Dec 12, 2016

  1. Slide 1: Corporate R&D

    6 Hiroaki Kasukawa, Ph.D. Corporate R&D Chief Technology Officer © Terumo Corporation

  2. Slide 2: Terumo R&D System

    Terumo R&D System CTO Collaborative effort to achieve a successful corporate growth strategy • Innovation for • Innovation for companies pipeline Company Evolution of Corporate future healthcare R&D core technologies R&D • Short- to mid-term • Long-term © Terumo Corporation Dec 12, 2016 1/14

  3. Slide 3: Contribute to Future of Healthcare with Significant Social Impact

    Contribute to Future of Healthcare with Significant Social Impact Chronic Stroke • Diseases that increase with age heart disease Pulmo- • Diseases that create large social burdens nology Mental Ophthal- disorder mology • Diseases that lead to business Ortho- opportunities pedics Regenerative medicin

  4. Slide 4: Chronic Heart Failure (CHF)

    Chronic Heart Failure (CHF) © Terumo Corporation Dec 12, 2016 3/14

  5. Slide 5: CHF Is Not Prevented by Treating Just One Disease

    CHF Is Not Prevented by Treating Just One Disease • Hypertension Chronic heart failure (CHF) • Myocardial infarction • Arrhythmia • Valve disease Decline in Disturbance in blood flow water balance • Cardiac toxicity of anticancer drugs Nephropathy CHF onset probability increases with age © Terumo Co

  6. Slide 6: Repeated Emergency Hospitalization in CHF

    Repeated Emergency Hospitalization in CHF Expenditure doubles with Unpredictable acute Hidden costs aging of society exacerbation CHF-related Cardiac 10T JPY function expenditure in U.S. Hospitali- zation • Emergency Hospitali- hospitalization zation 5T JPY • Declining operation Hospitali- zation ra

  7. Slide 7: Improvements after Heart Failure and Detection of Acute Worsening

    Improvements after Heart Failure and Detection of Acute Worsening Improve condition from Early detection of heart failure acute worsening Control heart pressure Remote monitoring HeartSheet Next gen. regenerative medicine Cloud and AI Cardiorenal syndrome (Improve blood flow) Proactive care © Terumo

  8. Slide 8: Cardiogenic Cerebral Infarction

    Cardiogenic Cerebral Infarction © Terumo Corporation Dec 12, 2016 7/14

  9. Slide 9: Cardiogenic Cerebral Infarction Tends to Have Severe Outcomes

    Cardiogenic Cerebral Infarction Tends to Have Severe Outcomes Expenditure increases with Severe and repetitive Hidden costs aging of society US health Recurrence expenditure rate 75% 47% 47% for strokes 18T JPY • Decline in QOL Mild • Care burden for family members 7T JPY Severe • Economic loss from

  10. Slide 10: Incidence Prevention and Reduced Damage from Aftereffects

    Incidence Prevention and Reduced Damage from Aftereffects Incident prevention Clot retrieval Reduced damage Clot Cerebral Prevent artery clot Local cell formation administration (via catheter) © Terumo Corporation Dec 12, 2016 9/14

  11. Slide 11: Regenerative Medicine

    Regenerative Medicine © Terumo Corporation Dec 12, 2016 10/14

  12. Slide 12: Evolution of Regenerative Medicine toward Commercialization

    Evolution of Regenerative Medicine toward Commercialization HeartSheet Commercialization Expansion to other diseases • Official approval • Allogenic cells Candidate diseases • Expanded indications • High volume production • Diabetic nephropathy • Peripheral artery disease • Stroke … i.e., local admi

  13. Slide 13: Transforming Engineering

    Transforming Engineering © Terumo Corporation Dec 12, 2016 12/14

  14. Slide 14: Collaborative Effort in On-site Engineering and Open Innovation

    Collaborative Effort in On-site Engineering and Open Innovation On-site Engineering Open Innovation From Academia seeds Hospital Partner companies In-house R&D From Cluster US west coast needs in Israel Ecosystem New method for Incubator value creation © Terumo Corporation Dec 12, 2016 13/14

  15. Slide 15: Innovating at the Speed of Life

    Innovating at the Speed of Life Accelerate R&D through Active Investment • R&D expense Double digits growth • Engineers Increase 40% from current (1,200) • Active external investment Contribute to future of healthcare with significant social impact © Terumo Corporation Dec 12, 2016 14/14

  16. Slide 16: © Terumo Corporation

    ~“TERUMO © Terumo Corporation

  17. Slide 17: Disclaimer

    Disclaimer The information that Terumo discloses and the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that

Terumo — Investor Presentation (December 2016) on 6ix